Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29888417 | 0.86 | CSNK2A1 (0.40) | CHEK1CSNK2A2CSNK2A1LRRK2 | |
| Adenine SCHEMBL28195376 | 0.81 | PI4KA (0.38) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| Tetrahydrofuran SCHEMBL130819 | 0.80 | CHEK1 (0.34) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL29804858 | 0.70 | CHEK1 (0.60) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| Purine SCHEMBL1705517 | 0.68 | KDM4A (0.31) | CHEK1PDPK1MAPK1PAK1 | |
| Guanine SCHEMBL886915 | 0.66 | KDM4E (0.49) | — | |
| Adenine SCHEMBL8110 | 0.64 | PI4KA (0.48) | PDPK1LRRK2 | |
| Adenine SCHEMBL3414603 | 0.64 | PI4KA (0.48) | PDPK1LRRK2 | |
| Adenine SCHEMBL3416954 | 0.64 | PI4KA (0.48) | PDPK1LRRK2 | |
| SCHEMBL9095851 | 0.63 | HTT (0.57) | CHEK1PDPK1MAPK1PAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20050085638-A1 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC (CA) | 2005-04-21 | — | — | US | disclosed |
| EP-1467990-A1 | PROCESS FOR PRODUCING DIOXOLANE NUCLEOSIDE ANALOGUES | Shire Biochem Inc. (CA) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062229-A1 | PROCESS FOR PRODUCING DIOXOLANE NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC. (CA) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085638-A1 | Process for producing dioxolane nucleoside analogues | NUDT1, DPYD, DUT | CHEK1 2207/4885PDPK1 648/4885MAPK1 902/4885 |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | NUDT1, DPYD, DUT | CHEK1 2207/4885PDPK1 648/4885MAPK1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.